Education
About Us
Working with TipRanks
Follow Us
Grifols SA (GRFS)
NASDAQ:GRFS
GRFS Stock Chart & Stats
$8.78
-$0.21(-2.68%)
At close: 4:00 PM EST
$8.78
-$0.21(-2.68%)
Day’s Range― - ―
52-Week Range$6.19 - $11.14
Previous CloseN/A
Volume119.87K
Average Volume (3M)710.42K
Market Cap
$7.56B
Enterprise Value$15.98B
Total Cash (Recent Filing)$824.65M
Total Debt (Recent Filing)$8.74B
Price to Earnings (P/E)13.7
Beta0.89
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.56%
Share Statistics
EPS (TTM)0.29
Shares Outstanding261,425,100
10 Day Avg. Volume573,323
30 Day Avg. Volume710,421
Financial Highlights & Ratios
PEG Ratio2.48
Price to Book (P/B)1.37
Price to Sales (P/S)0.95
P/FCF Ratio8.41
Enterprise Value/Market Cap2.11
Enterprise Value/Revenue2.13
Enterprise Value/Gross Profit5.55
Enterprise Value/Ebitda9.93
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.06
Revenue Forecast (FY)$9.25B
Bulls Say, Bears Say
Bulls Say
Vertical Integration In Plasma Supply ChainOwning donor centers, processing and distribution creates durable supply control and quality barriers to entry. This integration supports stable raw-material access, margin preservation and faster commercialization of new plasma-derived products across geographies over the next several years.
Improving Cash Generation And DeleveragingSustained improvement in operating cash flow and recent positive free cash flow supports deleveraging and refinancing capacity. Stronger cash conversion reduces reliance on external funding, enabling debt paydown and reinvestment in R&D and capacity over the medium term.
Regulatory Wins Expanding Supply And Product ReachEMA certification for Egypt-sourced plasma and other approvals broaden low-cost supply and market access. This structural expansion increases capacity, diversifies sourcing risk, and supports long-term product throughput and margin stability in global plasma therapies.
Bears Say
Elevated Leverage And Large Outstanding DebtHigh absolute debt limits financial flexibility and raises refinancing and interest-rate vulnerability despite recent reductions. Persistently elevated leverage constrains capital allocation, increases default risk under stress, and lengthens the time needed to restore balance-sheet resilience.
Thin And Volatile ProfitabilityModest margins and recent revenue deceleration reduce internal funding for R&D and capacity expansion. Persistent thin profitability makes earnings more sensitive to pricing, raw-material or FX shocks, limiting the firm’s ability to self-fund growth and accelerate deleveraging.
China Pricing Pressure And U.S. Regulatory DelaySustained pricing controls in China can structurally depress volumes and margins in a major market. Separately, delayed U.S. fibrinogen approval defers commercialization and ROI on the asset, compressing near-to-medium-term revenue and slowing portfolio-driven growth.
Grifols SA News
GRFS FAQ
What was Grifols SA’s price range in the past 12 months?
Grifols SA lowest stock price was $6.19 and its highest was $11.14 in the past 12 months.
What is Grifols SA’s market cap?
Grifols SA’s market cap is $7.56B.
When is Grifols SA’s upcoming earnings report date?
Grifols SA’s upcoming earnings report date is Apr 30, 2026 which is in 58 days.
How were Grifols SA’s earnings last quarter?
Grifols SA released its earnings results on Feb 26, 2026. The company reported $0.289 earnings per share for the quarter, missing the consensus estimate of $0.296 by -$0.007.
Is Grifols SA overvalued?
According to Wall Street analysts Grifols SA’s price is currently Overvalued.
Does Grifols SA pay dividends?
Grifols SA pays a Annually dividend of $0.142 which represents an annual dividend yield of 1.56%. See more information on Grifols SA dividends here
What is Grifols SA’s EPS estimate?
Grifols SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Grifols SA have?
Grifols SA has 261,425,100 shares outstanding.
What happened to Grifols SA’s price movement after its last earnings report?
Grifols SA reported an EPS of $0.289 in its last earnings report, missing expectations of $0.296. Following the earnings report the stock price went down -3.135%.
Which hedge fund is a major shareholder of Grifols SA?
Currently, no hedge funds are holding shares in GRFS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grifols SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
GRFS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 10.0%
Last 30 Days ▲ 10.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.68%
12-Months-Change
Fundamentals
Return on Equity
6.93%
Trailing 12-Months
Asset Growth
3.05%
Trailing 12-Months
Company Description
Grifols SA
Grifols SA is a global healthcare company headquartered in Barcelona, Spain, specializing in the production of plasma-derived therapies and biopharmaceuticals. The company operates primarily in the biotechnology sector, focusing on the development, manufacturing, and marketing of innovative products for the treatment of various medical conditions, including hemophilia, immunodeficiencies, and neurological disorders. Grifols' core products include immunoglobulins, albumin, and clotting factor concentrates, which are derived from human plasma and used in critical care settings and for patients with chronic diseases.
GRFS Company Deck
GRFS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights Grifols' robust financial performance, with significant revenue growth, improved adjusted EBITDA, and strengthened free cash flow. The company has made progress in deleveraging and gaining market share, particularly in the immunoglobulins franchise. However, challenges such as pricing pressures in China and exchange rate headwinds persist, along with a delay in regulatory approval for fibrinogen in the U.S. Despite these challenges, the overall sentiment leans towards positive, given the strong financial and operational metrics.View all GRFS earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
8.78% Mutual Funds
32.60% Other Institutional Investors
57.48% Public Companies and
Individual Investors